Investor Relations

LivaNova is commited to enhancing shareholder value driven by the mission and values that guide our company strategy. We are a market-leading medical technology and innovation company with a diverse global product portfolio and pipeline.

Explore Our Investor Kit
NASDAQ GS: LIVN
Day High
Day Low
Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Show all
June 16, 2023
2023 Annual General Meeting Polling Results
April 28, 2023
2022 UK Annual Report
April 28, 2023
2022 Annual Report on Form 10-K
April 28, 2023
2023 Proxy Statement and Notice of Annual General Meeting

Pro forma revenues by geography 1

  • Europe
  • United States
  • Rest of World

1) Rounded numbers based on full-year 2023 revenue.

Pro forma revenues by business 1

  • Cardiopulmonary
  • Neuromodulation
  • Advanced Circulatory Support

1) Rounded numbers based on full-year 2023 revenue.

News Listing Image

Recent Press Releases

March 21, 2024
LivaNova to Announce First-Quarter 2024 Results
March 20, 2024
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
March 5, 2024
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
March 4, 2024
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes